Valuation: Autolus Therapeutics plc

Market Cap 311M 282M 261M 236M 444M 29.36B 459M 3.14B 1.24B 15.68B 1.17B 1.14B 49.79B P/E 2026 *
-1.46x
P/E 2027 * -1.84x
Enterprise Value 177M 160M 148M 134M 252M 16.65B 260M 1.78B 705M 8.89B 663M 649M 28.23B EV / Sales 2026 *
1.16x
EV / Sales 2027 * 1.26x
Free-Float
99%
Yield 2026 *
-
Yield 2027 * -
1 day-1.68%
1 week-8.59%
Current month-23.03%
1 month-27.78%
3 months-47.30%
6 months-31.58%
Current year-41.21%
1 week 1.12
Extreme 1.12
1.38
1 month 1.12
Extreme 1.12
1.74
Current year 1.12
Extreme 1.12
2.58
1 year 1.12
Extreme 1.12
2.58
3 years 1.1
Extreme 1.105
7.45
5 years 1.1
Extreme 1.105
7.45
10 years 1.1
Extreme 1.105
53.24
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 53 01/09/2014
Chief Executive Officer 61 01/03/2016
Director of Finance/CFO 56 07/08/2023
Director TitleAgeSince
Chairman 61 01/10/2014
Director/Board Member 78 01/08/2014
Director/Board Member 71 01/03/2018
Date Insider Type Main position Quantity % Market Cap. Importance
2/9/26 Sell

Executive/Senior Manager

-6,713 0.0025%
29/6/26 Free

Director

79,167 0.0477%
18/3/26 Other

Chief Executive Officer

6,917,877 4.1641%
Change 5-day change 1-year change 3-year change Capi.($)
-1.68%-8.59%-8.59%-68.03% 311M
+1.26%+6.61%+41.12%+135.59% 1,286B
+0.79%+3.45%+46.35%+93.56% 688B
+0.20%+1.28%+27.01%+112.80% 521B
-0.44%+3.69%+39.60%+69.51% 386B
+0.55%+0.70%+59.00%+44.20% 364B
-0.12%+0.74%+26.78%+58.43% 302B
+0.37%+0.37%+3.62%+36.44% 287B
-0.30%+1.14%+38.59%+74.61% 252B
+0.08%+0.71%+34.25%+124.32% 208B
Average +0.07%+1.01%+30.77%+68.14% 429B
Weighted average by Cap. +0.54%+3.26%+37.63%+96.22%

Financials

2026 *2027 *
Net sales 152M 138M 127M 115M 217M 14.34B 224M 1.53B 607M 7.66B 571M 559M 24.32B 197M 178M 165M 149M 280M 18.54B 290M 1.98B 785M 9.9B 738M 722M 31.44B
Net income -215M -194M -180M -162M -306M -20.23B -317M -2.16B -857M -10.81B -805M -788M -34.31B -169M -153M -142M -128M -241M -15.96B -250M -1.7B -676M -8.53B -635M -622M -27.06B
Net Debt -135M -122M -113M -102M -192M -12.71B -199M -1.36B -538M -6.79B -506M -495M -21.56B -64.16M -58.14M -53.78M -48.52M -91.44M -6.05B -94.66M -646M -256M -3.23B -241M -236M -10.26B
Projected Income Statement - Annual - Autolus Therapeutics plc
Logo Autolus Therapeutics plc
Autolus Therapeutics plc is a United Kingdom-based early commercial-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. The Company has an approved commercial product, AUCATZYL, for the treatment of adult patients with r/r B-ALL. Using a suite of proprietary and modular T cell programming technologies, it is also developing five programs in seven hematological and solid tumor indications and one autoimmune indication. It is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and attack and eliminate these cells. Its product pipeline includes obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting TRBC 1 and TRBC 2.
Employees
753
Date Price Change Volume
13/11/26 USD 1.170 -1.68% 1,795,571
12/11/26 USD 1.190 -3.64% 2,573,301
11/11/26 USD 1.235 -6.44% 3,847,312
10/11/26 USD 1.320 0.00% 7,349,481
09/11/26 USD 1.320 +3.13% 4,488,979
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Autolus Therapeutics plc
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
1.170USD
Average target price
8.362USD
Spread / Average Target
+614.74%
  1. Stock Market
  2. Stocks
  3. AUTL Stock